Cholesterol-Lowering Claim Disease Status Protested By McNeil
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer Healthcare opposes FDA's classification of certain cholesterol-lowering claims as disease claims in the final rule on dietary supplement structure/function claims. In a Feb. 7 citizen petition, McNeil asks the agency to reconsider its decision.
You may also be interested in...
Mars CocoaVia Chocolate Bars Receive No Kudos In FDA Warning Letter
CocoaVia chocolate bars are adulterated "in that they contain a food additive, namely folic acid, which is unsafe within the meaning of section 409" of the FD&C Act, CFSAN Office of Compliance Director Joseph Baca tells Mars in a recent warning letter
Benecol, Statins Combined Use Outperforms Increased Statin Doses - Study
Concomitant use of McNeil Consumer Healthcare's Benecol spread with Rx statin drugs more effectively reduces total cholesterol and low-density lipoprotein (LDL) cholesterol levels than a doubled dose of the original statin, a recently published study reports.
Cholesterol Claim Clarification To Be Covered In Upcoming FDA Guidance
"Inconsistencies" in FDA's handling of "philosophically-related" cholesterol claims will be addressed in the agency's upcoming guidance on dietary supplement structure/function claims, the Center for Food Safety & Applied Nutrition's Robert Moore, PhD, told a FDLI meeting on supplement regulation in Washington, D.C. June 26.